Presentasjon lastes. Vennligst vent

Presentasjon lastes. Vennligst vent

Light-Directed Drug Delivery Nanoteknologi for styrt medisinering Anders Høgset, Nanomat-seminar 28. Mai 2008.

Liknende presentasjoner


Presentasjon om: "Light-Directed Drug Delivery Nanoteknologi for styrt medisinering Anders Høgset, Nanomat-seminar 28. Mai 2008."— Utskrift av presentasjonen:

1 Light-Directed Drug Delivery Nanoteknologi for styrt medisinering Anders Høgset, Nanomat-seminar 28. Mai 2008

2 2 Disposisjon PCI Biotech AS Målrettet legemiddellevering med nanoteknologi PCI Biotechs teknologi – lysdirigert levering av nanomedisin PCI Biotechs utvikling - samarbeid – støtteordninger

3 3 PCI Biotech AS Kommersialisere patentert teknologi for levering av legemidler - fotokjemisk internalisering (PCI) Ny metode for kreftbehandling – lysdirigert legemiddellevering Kraftigere virkning i kreftsvulst Mindre bivirkninger Teknologien kan forbedre virkningen av mange typer legemidler: Cellegifter – klinisk studie start 2008 Makromolekyler (proteiner, siRNA, gener) Nanomedisiner PCI Biotech vil tjene penger ved å lisensisere ut teknologien til firmaer som har legemidler PCI kan forbedre. Upfront-betaling Milepelsbetaling Royalties

4 4 PCI Biotech AS 6 ansatte (2 hovedkvarter - 4 Radiumhospitalet) Rekruttering pågår Arbeider via samarbeidspartnere Samarbeidsavtale med Radiumhospitalet Teknologien oppfunnet der Ca. 15 personer arbeider med PCI teknologien Datterselskap av Photocure ASA (OSE: PHO) Andre eiere: Radiumhospitalets Forskningsstiftelse, ansatte Fisjoneres fra Photocure NÅ Betydelig finansiering fra offentlige kilder (NFR, EU) Ca. NOK 22 mill. til nå Ca. NOK 7 mill. per år i 2008 og 2009 Planlagt notert på Oslo Børs (Oslo Axess) i juni 2008 Hente inn NOK mill. i ny egenkapital Aksjetegning pågår.

5 5 Disposisjon PCI Biotech AS Målrettet legemiddellevering med nanoteknologi PCI Biotechs teknologi – lysdirigert levering av nanomedisin PCI Biotechs utvikling - samarbeid – støtteordninger

6 6 Drug delivery - general Make drugs reach their body target in an optimal way Market: NOK 450 billion per year Growing % per year Increasing need because of more “advanced” drug molecules –Genes –Oligonucleotides –Proteins –Nanomedicines

7 7 Challenge in cancer therapy Common situation Desired situation How ? - Targeted delivery Killing cancer cells is not difficult! Lots of drugs can do this But, effect not specific side effects

8 8 Drug targets and drug delivery to cells Drug target: Molecule in the body that interacts with drug Physical interaction gives therapeutic effect Targeted delivery - If drug is taken up only into cancer cells it can only have effect there - Normal cells will be spared Drug target Drug Desired effect cell membrane Side effect X

9 9 Nanoparticles to carry drug to target cell Protect drugs that are degraded in the body Change route for traveling through the body drug Nanoparticle shell - Lipid - Polymer

10 10 Antibodies for targeting nanoparticles to specific cells drug nm Antibodies:- Can bind to surface features specific for cancer cells - Can be used for delivering drugs specifically to such cells

11 11 Other kinds of nanostructures for drug delivery Antibodies with drugs directly attached Binds to surface of target cell 9 nm

12 12 Nanomedicines on the market Liposomal cytotoxic drugs Protein conjugates Cytotoxic drug attached to albumin Antibody conjugates Cytotoxic drugs Radioisotopes Targeted

13 13 Disposisjon PCI Biotech AS Målrettet legemiddellevering med nanoteknologi PCI Biotechs teknologi – lysdirigert levering av nanomedisin PCI Biotechs utvikling - samarbeid – støtteordninger

14 14 Nanoparticles usually taken up by endocytosis Therapeutic effect Endosomal release Endo- some Lyso- some Getting drug to right place within the cell Endocytosis

15 15 Photochemical internalisation (PCI) - light-induced endosomal release of nanoparticles Therapeutic effect Light Light energy in Chemical energy out Drug delivery 1,2 nm Amphinex TM Photosensitiser: ”Nanomachine” making it possible to exploit the energy in light for targeting drug delivery.

16 16 GFP + Hoechst Photosensitiser (in endosomes) Pål K. Selbo Illumination induces rupture of endosomes Before illumination: photosensitiser in endosomes

17 17 GFP + Hoechst Photosensitiser (cytosolic release) after microscopy light exposure After illumination: photosensitiser in cytosol Pål K. Selbo Illumination induces rupture of endosomes

18 18 Photochemical internalisation (PCI) Patented Photosensitiser Amphinex TM + light Drug activated only in illuminated region (e.g. tumour) Targeting drug delivery by illumination

19 19 PCI enhances antibody mediated drug delivery in animal model (Selbo et al., in preparation) PCI + ITX ITX alone Un- treated PCI + ITX Melanoma antibody carrying toxin (immunotoxin – ITX)

20 20 Gene that makes cancer cells commit suicide Gene delivered by targeted (polymer) nanoparticle. PCI in nanoparticle-based gene therapy (Ndoye et al., 2006)

21 21 Disposisjon PCI Biotech AS Målrettet legemiddellevering med nanoteknologi PCI Biotechs teknologi – lysdirigert levering av nanomedisin PCI Biotechs utvikling - samarbeid – støtteordninger

22 22 History of PCI Biotech 1995 PCI technology enhances effect of anti-cancer drug PCI Biotech Formed Core PCI technology developed at the Radium Hospital patented PCI Biotech signed agreement with Radium Hospital Research Foundation Top management recruited Start of first clinical study Demerger from Photocure Efficient cancer gene therapy induced by the PCI technology Patent granted on Amphinex for PCI Biotech PCI Biotech acquired patent application for combination of siRNA and the PCI technology In vivo proof of concept for certain oncology compounds In vivo proof of concept for macromolecules

23 23 PCI Biotech and the Norwegian Radium Hospital (NRH) PCI technology was invented at NRH (Kristian Berg) NRH Research Foundation (RF) owns about 7 % of shares in PCI Biotech PCI Biotech has a ”general” research agreement with NRH Possibilities for contract research Right to use results within FIELD Right to aquire inventions (right of first refusal) within FIELD. Clinicians followed development of technology Collaboration with RF/NRH has generally run smoothly with established routines and negligible bureaucracy

24 24 Synthetica AS Photocure PCI Biotech Radium- hospitalet, forskning PCI Biotech – relasjoner EU-prosjekt: Nanoteknologi Folkehelse- instituttet Akademiske samarbeids- partnere: England, Nederland, Frankrike, Tyskland, Italia Belgia Radiumhospitalet, klinikk NFR Radium forsknings- stifelse Senter for forsknings- drevet innovasjon: Stamceller Kommersielle samarbeidspart. /lisenstakere Oslo Cancer Cluster

25 25 PCI Biotech goals Completed 6 clinical Proof of Concept studies with cytotoxic compounds 2 licence deals for Amphinex in combination cytotoxic compounds 1 licence deal for Amphinex in the macromolecule/nanomedicine space Initiated development of a next generation photosensitiser PCI Biotech in 2012

26 26 PCI Biotech – kommersialisering og offentlig støtte Ennå ca. 3 år før PCI Biotech vil begynne å få inntekter Privat kapital innhentes for å nå dit NOK 60 mill. garantert i nåværende emisjon Offentlige støtte har vært (og er) helt essensielt for utviklingen av selskapet Nødvendig for å drive forskningen fram til dagens stadium Viktig overfor investorer –Kvalitetsstempel –Mindre risiko Pådriver for samarbeidsprosjekter –Økt kompetanse også hos samarbeidspartnere Viktig for videreutvikling av teknologien og selskapet –Teknologi med mange anvendelsesområder –Viktig å identifisere, dokumentere og kommersialisere slike bruksområder innenfor patentlevetid –Samarbeidsprosjekter

27 27 PCI Biotech and nanomedicine Important area for the future –PCI technology very well suited for use in nanomedicine –Clinical study with cytotoxic substance will be important also for nanomedicines EU project MEDITRANS - Targeted delivery of nanomedicines –Start jan –Integrated project, 29 partners (  NOK 100 mill. from EU) Nanomedicines in cancer and inflammatory diseases Nanoparticles in delivery of siRNA and genes Develop nanoparticles for light induced drug delivery.

28 28 Takk for oppmeksomheten


Laste ned ppt "Light-Directed Drug Delivery Nanoteknologi for styrt medisinering Anders Høgset, Nanomat-seminar 28. Mai 2008."

Liknende presentasjoner


Annonser fra Google